Astellas US LLC et al v. Glenmark Pharmaceuticals Limited

DocketPro Hac Vice Attorney Kimberly A. Kennedy for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) (Entered: 06/11/2020)

DocketPro Hac Vice Attorney Ben Katzenellebogen for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) (Entered: 06/11/2020)

DocketPro Hac Vice Attorney Joseph M. Reisman for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) (Entered: 06/11/2020)

DocketPro Hac Vice Attorney William R. Zimmerman for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) (Entered: 06/11/2020)

Docket(#12) ANSWER to #10 Answer to Complaint, Counterclaim to Defendant's Counterclaim by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Oakes, Robert) (Entered: 06/10/2020)

Docket(#11) Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Green, James) (Entered: 06/08/2020)

Docket(#10) ANSWER to #1 Complaint, of Glenmark Pharmaceuticals Limited, COUNTERCLAIM against All Plaintiffs by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Green, James) (Entered: 06/08/2020)

DocketSO ORDERED, re #9 MOTION for Pro Hac Vice Appearance of Attorney Ben Katzenellebogen, Joseph Reisman, Kimberly A. Kennedy and William R. Zimmerman filed by Glenmark Pharmaceuticals Limited. Signed by Judge Colm F. Connolly on 6/2/2020. (fms) (Entered: 06/02/2020)

Docket(#9) MOTION for Pro Hac Vice Appearance of Attorney Ben Katzenellebogen, Joseph Reisman, Kimberly A. Kennedy and William R. Zimmerman - filed by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certification of Ben Katzenellebogen, #2 Certification of Joseph Reisman, #3 Certification of Kimberly Kennedy, #4 Certification of William R. Zimmerman)(Green, James) (Entered: 06/02/2020)

DocketSO ORDERED, re #8 STIPULATION TO EXTEND TIME for Defendant to move, answer, or otherwise respond to the Complaint to June 8, 2020 filed by Glenmark Pharmaceuticals Limited, Set/Reset Answer Deadlines: Glenmark Pharmaceuticals Limited answer due 6/8/2020. Signed by Judge Colm F. Connolly on 5/6/2020. (fms) (Entered: 05/06/2020)

Docket(#8) STIPULATION TO EXTEND TIME for Defendant to move, answer, or otherwise respond to the Complaint to June 8, 2020 - filed by Glenmark Pharmaceuticals Limited. (Green, James) (Entered: 05/06/2020)

DocketCase Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 04/22/2020)

Docket(#7) SUMMONS Returned Executed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc.. Glenmark Pharmaceuticals Limited served on 4/17/2020, answer due 5/8/2020. (Oakes, Robert) (Entered: 04/17/2020)

DocketNo Summons Issued. (mal) (Entered: 04/16/2020)

Docket(#6) Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gilead Sciences, Inc.. (mal) (Entered: 04/16/2020)

Docket(#5) Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas US Holding, Inc. for Astellas Pharma US, Inc., Astellas US LLC. Astellas Pharma Inc. is the sole shareholder of Astellas US Holding, Inc. filed by Astellas Pharma US, Inc., Astellas US LLC. (mal) (Entered: 04/16/2020)

Docket(#4) Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE 47,301 E ;US 8,524,883. (mal) (Entered: 04/16/2020)

Docket(#3) Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 2, 2020. Date of Expiration of Patent: February 2, 2027.Thirty Month Stay Deadline: October 2, 2022. (mal) (Entered: 04/16/2020)

Docket(#2) Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) (Entered: 04/16/2020)

Docket(#1) COMPLAINT FOR PATENT INFRINGEMENT - filed against Glenmark Pharmaceuticals Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2900469.) - filed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Civil Cover Sheet)(mal) (Entered: 04/16/2020)